Accordingly, GLP-1 RA treatment has been shown to directly or indirectly improve cardiometabolic risk factors that characterise diabetes and obesity, and which play central roles in the development or exacerbation of CVD, including HF. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.